Figure 4.

Risk of CVD and cardiovascular events, type 2 diabetes (T2D), and all-cause and/or CVD event mortality in MHO. Metabolically healthy lean (MHL) served as a reference group, and the mean relative risk for incident diseases, events, or mortality was compared between the MHO group (defined as absence of any metabolic abnormalities) and a group of individuals with MUO. Data are extracted from previous meta-analyses (34, 79, 80) or a large recent cohort study (43). For data from reference (44), only the subgroup of MUO with 3 metabolic comorbidities (= highest relative risk) is displayed despite evidence for gradually increasing risk (in all categories) with the increased number of metabolic abnormalities (ranging from 1–3).